Menu
Search
|

Menu

Close
X

CytomX Therapeutics Inc CTMX.OQ (NASDAQ Stock Exchange Global Select Market)

12.07 USD
-0.04 (-0.33%)
As of 1:12 PM EDT
Previous Close 12.11
Open 12.01
Volume 23,349
3m Avg Volume 165,389
Today’s High 12.17
Today’s Low 11.87
52 Week High 27.19
52 Week Low 8.94
Shares Outstanding (mil) 36.87
Market Capitalization (mil) 792.65
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.90 Mean rating from 10 analysts

KEY STATS

Revenue (mm, USD)
FY19
29
FY18
60
FY17
72
FY16
15
EPS (USD)
FY19
-0.313
FY18
-1.995
FY17
-1.842
FY16
-1.626
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
26.31
7.92
Price to Book (MRQ)
vs sector
15.16
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
0.00
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
-26.13
14.49
Return on Equity (TTM)
vs sector
-81.04
15.79

EXECUTIVE LEADERSHIP

Sean McCarthy
Chairman of the Board, President, Chief Executive Officer, Since 2018
Salary: $550,000.00
Bonus: --
Lloyd Rowland
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary, Since 2018
Salary: $208,789.00
Bonus: --
Nick Galli
Senior Vice President, Chief Business Officer, Since 2019
Salary: --
Bonus: --
W. Michael Kavanaugh
Chief Scientific Officer and Head - Research and Non-Clinical Development, Since 2015
Salary: $427,357.00
Bonus: --
Rachel Humphrey
Chief Medical Officer, Since 2015
Salary: $440,448.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

151 Oyster Point Blvd Ste 400
SOUTH SAN FRANCISCO   CA   94080-1910

Phone: +1650.5153185
Site: cytomx.com/

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.

SPONSORED STORIES